03:49 PM EST - Algernon Pharmaceuticals Inc. : has received a No Objection Letter from Health Canada to proceed with a NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory authorities. Algernon Pharmaceuticals Inc.
shares AGN:CNX are trading up $0.02 at $0.47.
